The World Anti-Doping Agency (WADA) is pleased to publish the new Technical Document for Sport Specific Analysis (TDSSA) (version 4.0), which includes amendments recently approved by the Agency’s 14 November 2018 Executive Committee (ExCo) meeting in Baku, Azerbaijan.
Please note that the following changes are scheduled to come into force on 1 January 2019:
- Athlete Biological Passport (ABP) – Haematological Module
a) The mandatory implementation of the ABP haematological module will now apply to all athletes from those sports/disciplines with an Erythropoiesis Stimulating Agents’ (ESAs) Minimum Level of Analysis (MLA) of 30% or greater (as identified in the TDSSA) who are part of an Anti-Doping Organization’s (ADO’s) Registered Testing Pool (RTP).
[Note: In November 2016, the ExCo approved the mandatory implementation of the ABP haematological module by ADOs for the sports/disciplines with an ESAs MLA of 30% or greater to come into effect on 1 January 2018. This was subsequently deferred to 1 January 2019.]
b) The ABP program must be compliant with all applicable ABP Technical Documents and International Standards, including the Technical Document for Athlete Passport Management Units (TD-APMU) [effective 1 March 2019].
c) All ADOs will be required to plan, at a minimum, an average of three ABP blood tests annually across all athletes from those sports/disciplines with an ESAs MLA of 30% or greater who are part of an ADO’s RTP.
d) The distribution of these tests should be carried out according to the status of the athlete’s ABP, as well as any intelligence that the ADO may have access to and the recommendations of the APMU. This will ensure that athletes with atypical/suspicious ABPs receive more tests than those athletes with normal ABPs.
WADA encourages ADOs with joint jurisdiction over an athlete to collaborate on testing plans and strategies. These ADOs may also combine ABP blood tests in order to achieve the average minimum numbers.
WADA will work closely with ADOs that are in the process of establishing an ABP haematological module and will monitor the implementation of such programs as part of the Agency’s wider Compliance Monitoring Program.
Should you have any questions regarding the implementation of an ABP program, please contact firstname.lastname@example.org.
2. Growth Hormone (GH)
Please note that the mandatory implementation of the GH MLAs for all sports/disciplines, which was due to come into force on 1 January 2019, will now be postponed until the endocrine module of the ABP is ready for implementation. In the meantime, ADOs are encouraged to continue to collect samples for GH and attempt to meet the GH MLAs. Please note that the MLAs for Growth Hormone Releasing Factors (GHRFs) remain mandatory.
Please also note that a stakeholder consultation process for a review of the TDSSA will commence in early 2019.
ADOs that have questions or comments regarding the TDSSA are invited to contact WADA at email@example.com.